Heart Failure (HF) is a complex disease associated with the highest burden of cost to the healthcare system. The cardiopulmonary exercise test (CPET) is instrumental in determining the prognosis of patients with HF. This multicentre study will validate whether aggregate biometric data from the Apple Watch combined with demographic, cardiac, and biomarker testing can improve our ability to predict heart failure outcomes among a diverse outpatient HF population.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* broad age range (\> 18 years of age)
* NT-proBNP \> 400 or 1000 if in AF
* Within 3 months post discharge from HF hospitalization/ HF ED visit/ HF rapid clinic visit with intensification of diuretic therapy
* NYHA functional class I-IV, heart failure with reduced and preserved ejection fraction
* Literacy in English
* Patient provided informed consent
Exclusion Criteria:
* Unable to perform a CPET based on the standard protocol
* End stage renal disease requiring dialysis
* Living with LVAD
* MRP deems patient unfit for the study
* Post heart transplant
Primary outcome measure(s)
Prediction of Cardiopulmonary Exercise Test Parameters — 7 months Measure the predictive power of cardiorespiratory fitness estimated from data obtained from Apple Watch in combination with clinical and/or demographical data against reductions in measured cardiorespiratory fitness, using K5 device in heart failure patients
Prediction of worsening heart failure — 7 months Measure predictive power of cardiorespiratory fitness estimated from data obtained from Apple Watch in combination with clinical and/or demographical data against worsening heart failure from clinical visits, bloodwork, and medication changes.
Trial sites (3)
Facility
City
Region
Status
Southlake Health
Newmarket
Ontario
Not Yet Recruiting
200 Elizabeth Street
Toronto
Ontario
Recruiting
Sunnybrook Health Sciences Center
Toronto
Ontario
Not Yet Recruiting
More University Health Network, Toronto trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.